Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This clinical trial is the first-in-human study of BBT-176. The purpose of this trial is to
investigate the safety and tolerability of BBT-176 (Part 1) and to evaluate the anti-tumor
activity of BBT-176 (Part 2).